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PXR activators are used to treat pruritus in chronic inﬂammatory liver diseases such as primary biliary
cirrhosis (PBC). The aims of this studywere to determinewhether PXR activators could have an additional
beneﬁt of inhibiting inﬂammation in the liver, and determine whether cyclosporin A – which more
effectively prevents PBC recurrence in transplanted patients than FK506 – is a PXR activator. In SJL/J mice
(which have constitutively high levels of hepatic portal tract inﬂammatory cell recruitment), feeding a
PXR activator inhibited inﬂammation, TNF and Il-1 mRNA expression in SJL/J-PXR+/+, but not SJL/J-
PXR−/−. Monocytic cells – a major source of inﬂammatory mediators such as TNF – expressed the PXR
and PXR activators inhibited endotoxin-induced NF-B activation and TNF expression. PXR activation
also inhibited endotoxin-stimulated TNF secretion from liver monocytes/macrophages isolated from
PXR+/+ mice, but not from cells isolated from PXR−/− mice. To conﬁrm that PXR activation inhibits NF-B
in vivo, 3x-B-luc ﬁbrotic mice (which express a luciferase gene regulated by NF-B) were imaged after
treatment with the hepatotoxin CCl4. PXR activator inhibited the induction of hepatic NF-B activity
without affecting CCl toxicity/hepatic damage. Using a PXR reporter gene assay, cyclosporin A – but4
not FK506 – was shown to be a direct PXR activator, and also to induce expression of the classic PXR-
regulated CYP3A4 gene in human hepatocytes and in a cell line null for the FXR, a nuclear receptor with
similar properties to the PXR. Conclusion: PXR activation is anti-inﬂammatory in the liver and the effects
of cyclosporin A in PBC disease recurrence may be mediated in part via the PXR. Since PXR activation
promotes hepatocyte growth and is also anti-ﬁbrogenic, the PXR may be an excellent drug target for the
mma
 treatment of chronic inﬂa
. IntroductionThe pregnane X receptor (PXR) is a member of the nuclear
eceptor gene superfamily of ligand-activated transcription factors
xpressed most prominently in hepatocytes and gut epithelium
Abbreviations: ALT, alanine aminotransferase; CsA, cyclosporin A; GT, gliotoxin;
APDH, glyceradehyde 3 phosphate dehydrogenase; HYP, hyperforin; IKK2-
n, IB kinase 2 inhibitor; LPS, lipopolysaccharide; METYR, metyrapone; MTS,
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
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[1]. The ligand binding site of the PXR is activated by a range of
structurally diverse xenobiotics such as the antibiotic rifampicin
(RIF) and endobiotics (e.g. bile acids) [2]. On activation, the PXR
regulates the expression of a sub-set of genes encoding drug
metabolising (e.g. CYP3A) and drug transporter proteins (e.g.
MRP2), that contain response elements within their promot-
ers [3]. The canonical function of the PXR is therefore to sense
elevations in xenobiotics and endobiotics and to orchestrate a
response that promotes xenobiotic/endobiotic metabolism and
excretion [4].
Recent work in this laboratory has revealed that the PXR has
a non-canonical function that results in an inhibition in the pro-
gression of liver ﬁbrosis [5–8]. Human ﬁbrogenic myoﬁbroblasts
express signiﬁcant levels of PXR mRNA and protein and treat-
Open access under CC BY license.ment with PXR activators inhibits their trans-differentiation from
hepatic stellate cells to ﬁbrogenic myoﬁbroblasts; inhibits myoﬁ-
broblast expression of the major pro-ﬁbrogenic cytokine TGF and
markedly slows myoﬁbroblast proliferation in vitro [6]. Using mice
with a disrupted PXR gene, it was also shown that pregnenolone
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6 carbonitrile (PCN), a potent activator of rodent PXR (but which
nly weakly activates the human PXR [9]), inhibited ﬁbrosis in vivo
n a PXR-dependent manner [5].
These observations may be of signiﬁcant clinical value because
ome chronic liver disease patients are treated with PXR activators
or extended periods, most notably patients with primary biliary
irrhosis (PBC). PBC is an inﬂammatory liver disease of unknown
etiology [10,11]. It is characterised by immune cell recruitment
o the portal tracts of the liver and progressive destruction of the
ntra-hepatic bile ducts [10,11]. Resultant cholestasis over many
ears leads to chronic liver damage, ﬁbrosis and cirrhosis. There is
o treatment for PBC but many patients are often treated with the
XR activator RIF [12–14]. However, the rationale for its use is that
t reduces pruritus [10,11].
A major regulator of inﬂammation is the transcription fac-
or NF-B which regulates the expression of a diverse array of
enes associated with both innate and adaptive immunity (includ-
ng many cytokines, chemokines, adhesion proteins and stress
esponse genes [15]). Recently, it has been shown that the p65
ub-unit of NF-B interacts with the PXR dimerisation partner
XR, and disrupts binding to promoters [16]. This interaction
ay account for the inhibition in drug metabolism by inﬂam-
ation [17]. However, it is now clear that the interaction of
F-B with the PXR has a reciprocal inhibitory effect on NF-
B activity [18]. This has been clearly documented in the gut,
hich has increased NF-B target gene expression in PXR null
ice [18]. This may be of relevance to humans since PXR poly-
orphisms have been linked to increased inﬂammation of the
owel in man [19]. More recently, it has been shown that PCN
a rodent-speciﬁc activator of the PXR) inhibits the expression of
everal – but not all – NF-B-dependent inﬂammatory genes in
mouse model of inﬂammatory bowel disease, an effect lost in
XR−/− mice [20].
We demonstrate in this paper that feeding the PXR activator
CN to SJL/J-PXR+/+ mice reduced levels of the pro-inﬂammatory
ytokines TNF and Il-1 in the liver and the number of inﬂamma-
ory cells around the portal tracts. These effects of PXR activator
ere lost in PXR−/− mice. We show that PXR was expressed in
nﬂammatory cells; that PXR activators inhibited NF-B activity
nd that hepatic NF-B is inhibited by PXR activation in vivo using
ive whole body imaging. Finally, we demonstrate that cyclosporin
(CsA) is a PXR activator, which may account for the bene-
cial effects of this anti-rejection drug (which delays disease
ecurrence in transplant recipients with PBC) compared to FK506
21,22].
. Materials and methods
.1. Materials
d-Luciferin was obtained from Synchem (Altenburg, Germany).
ecombinant human tumour necrosis factor- (TNF) and hyper-
orin (HYP) were purchased from Calbiochem (Nottingham, UK).
Cl4, PCN, endotoxin/lipopolysaccharide (LPS) from E. coli 0111:B4,
IF,metyrapone (METYR), CsA and FK506were purchased from the
igma Chem Co. (Poole, UK). The IB kinase 2 inhibitor (IKK2-In)
as a generous gift from Wyeth Research. All other reagents were
f the highest purity available from local commercial sources. Note
hat there are important species differences in the ligands that acti-
ate PXR. The classic rodent PXR activator PCN is a weak activator
f the human PXR [4]. Accordingly, PCN has been used primarily as
n activator in studies with mice whereas the classic human PXR
ctivator RIF and other activators have been used in studies with
uman cells.& Molecular Biology 120 (2010) 137–148
2.2. Animals
Wild type SJL/Jmice initially supplied byCharles River (Margate,
UK) were crossed with C57Bl6 PXR−/− mice (originally obtained
from Dr Steven Kliewer, University of Texas, USA [23]) to generate
heterozygous (PXR+/−) animals. Thesemicewere thenback-crossed
6 times with wild type SJL/J mice to produce PXR+/− mice on an
SJL/J background and then crossed to generate SJL/J-PXR+/+ and
SJL-PXR−/− colonies. Mice were routinely genotyped by two sepa-
rate PCR reactions to detect wild type and knockout alleles in DNA
derived from tail tips as outlined [5].
3x-B-luc C57BL/6J×CBA/J mice (bearing a transgene com-
posed of three NF-B sites from the Ig light chain promoter
coupled to the gene encoding ﬁreﬂy luciferase)were generated and
genotyped as previously described [24].
2.3. Animal studies
To assess the effects of PXR activation on portal tract inﬂamma-
tion (PTI), female mice (which show constitutively greater levels of
PTI than males and signiﬁcant increases in response to treatment
with the E2 sub-unit of the pyruvate dehydrogenase [25]) were
acclimatized to powder diet for 1 week prior to addition of PCN to
treated groups at 0.025% (w/w) for 8 weeks.
CCl4 was used to cause liver damage in mice (25–30g body
weight) by administration of 1.0ml CCl4/kg body weight (using
1:1 (v/v) CCl4: corn oil mixture by i.p. injection twice weekly for 4
weeks. Control animals received equivalent vehicle injections. PCN
was co-administered at 100mg/kg body weight as a suspension in
the CCl4/vehicle or vehicle alone 24h prior to endpoints only.
2.4. RT-PCR
Total RNA was puriﬁed from cells using Trizol (Invitrogen,
Paisley, UK) and DNase I (Promega, Southampton, UK) treated to
remove any contaminating genomic DNA. RT-PCR was performed
and analysed essentially as previously outlined with gene spe-
ciﬁc primer sequences (Supplementary Table 1) [6]. Quantitative
analysis of speciﬁc mRNA expression was performed by real-
time qRT-PCR using SYBR green chemistry (or Applied Biosystem
Taqman Hs00243666-m1, which detects all 3 human PXR mRNA
transcripts) and an Applied Biosystems 7500 Fast Real-Time PCR
System(PerkinElmer-AppliedBiosystems, FosterCity, CA). Relative
differences in target gene mRNA expression were assessed for each
sample, in triplicate, along with appropriate no template controls
after normalization of the total amount of tested cDNA to an 18S
rRNAendogenous reference (Cat#: 4308329, Perkin Elmer-Applied
Biosystems, Foster City, CA).
2.5. Pathology
Livers were excised, divided and ﬁxed in formalin or snap
frozen in liquid nitrogen and stored at −80 ◦C for later analysis.
Formalin-ﬁxed liver was embedded in wax and sections stained
with haemotoxylin and eosin [5]. PTI was determined in at least 10
randomly selected portal tracts per animal by an examiner blinded
to the treatment groups. Another blinded examiner then calculated
the total area of bile duct present in each ﬁeld of view. The two sets
of data were then combined to generate an inﬂammatory score
normalised to bile duct area.2.6. Cell culture
The human monocytic cell lines THP-1 and U937-3XB-LUC
(stably transfected with an NF-B responsive luciferase reporter
construct [26]) were cultured in RPMI supplemented with 10% FCS,
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0g/ml penicillin and 80g/ml streptomycin. The LX-2 (stellate)
nd Hep-G2 (hepatoma) human cell lines were cultured as pre-
iously outlined [6]. The human colon cancer cell line LS180 was
btained from Prof Ann Daly (Newcastle University, UK) and was
ultured in the same manner as Hep-G2 cells. Human Kupffer cells
ere isolated from the non parenchymal cell pellet obtained after
ensity gradient centrifugation with Optiprep (Sigma) during iso-
ations for hepatic stellate cells as outlined [6], then through their
apid adherence to cell culture plastic for 10min at 37 ◦C. Exten-
ive washing with Hank’s balanced salt solution (HBSS, 137mM
aCl, 5.4mM KCl, 0.44mM KH2PO4, 0.34mM Na2HPO4, 5.6mM
lucose, 6mM HEPES, 4.1mM NaHCO3 and 30M phenol red
H 7.4) resulted in >90% Kupffer cells as judged by immunocy-
ochemical analyses and the uptake of latex beads [27]. Kupffer
ells were cultured in serum-free RPMI medium (Invitrogen)
upplemented with 80g/ml penicillin, 80g/ml streptomycin
nd 32g/ml gentamycin for 2h prior to experimental use. Cell
iability was determined by either mixing cell suspensions 1:1
v/v) with 0.4% (w/v) trypan blue and assessing the percent-
ge number of cells excluding the dye within 5min, or by using
he ([3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
-(4-sulfophenyl)-2H-tetrazolium salt (MTS) assay (Promega,
outhampton, UK). In brief, cells were incubated for 3h with the
TS dye essentially as outlined by the manufacturers and then dye
eduction determined by measuring absorbance at 490nm using
96-well plate reader. The use of human liver cells for scientiﬁc
esearch was approved by the Grampian Regional Ethics and New-
astle and North Tyneside Local Regional Ethical Committee 2 and
as subject to informed patient consent. Up to 10 mice for each
enotypewere used for isolation ofmurine Kupffer cells. Cell geno-
ype was checked by PCR as outlined [5] to conﬁrm cells were all
f the correct genotype. Mouse cells were cultured as outlined for
uman Kupffer cells.
.7. Immunocytochemistry
Cellswere ﬁxed and immunostained essentially as described [6]
sing either an anti-ED1 (CD68) mouse monoclonal (Serotec); an
nti--actin mouse monoclonal (Chemicon, Chandlers Ford, UK);
r a rabbit polyclonal anti-CD115 serum (Abcam, Cambridge, UK).
hodamine red-conjugated anti-mouse IgG (Jackson) and/or FITC-
onjugated anti-rabbit IgG (Abcam, Cambridge, UK) incubationwas
ollowedbyﬂuorescencemicroscopy to visualise stained cells. Cells
tained without the addition of primary antibody acted as controls,
ith control photomicrographs obtained under identical illumina-
ion and exposure conditions.
.8. Transfection and reporter gene assays
THP-1 cells were transfected by electroporation using a Biorad
ene Pulser. Brieﬂy, 5×106 cells were washed twice in serum-free
edium and re-suspended in 700l of serum-free medium con-
aining a total of 40g of plasmid and incubated on ice for 10min.
he cells were then subjected to a single pulse at 0.23kV, 960f,
ncubated on ice for 10min followed by 10min at room tempera-
ure prior to dilution into 12ml of serum-containing medium. LX-2
ellswere transfectedusinggenejuice (Calbiochem, Loughborough,
K) essentially as previously outlined [6]. TNF-Prom (containing
260 nucleotides of the mouse proximal TNF promoter inserted
nto the pXP1 vector [28]) and the empty pXP1 vector were orig-
nally obtained from Prof Peter Johnson (NCI, Frederick, USA).
ER6)3-pGL3promoter was originally described for the determin-
ng PXR activation [6]. In all cases, cells were co-transfected with a
ontrol renilla reporter construct (RL-TK, Promega, Southampton,
K). Reporter gene expressionwas assayedby luminometry using a
ual Luc kit (Promega, Southampton, UK) and luciferase expression& Molecular Biology 120 (2010) 137–148 139
normalised to renilla expression. Luciferase expression in U937-
3XB-LUC cells stably transfected with luciferase was determined
also using the Dual Luc kit.
2.9. FACS analysis
Fluorescence activated cell sorting was used to analyse pop-
ulations of cells in the sub-G1 phase of the cell cycle. Brieﬂy,
U937-3XB-LUC cells were washed twice with PBS by centrifuga-
tion at 500× g (3min at 25 ◦C) before re-suspension in hypotonic
ﬂuorochrome solution (50g/ml propidium iodide, 0.1% (w/v)
sodium citrate and 0.1% (v/v) Triton X-100). FACS analysis was car-
ried out using a BD Facscan Flow Cytometer (Becton Dickinson, UK)
anddata analysiswithCellQuestTM ProSoftware (BectonDickinson,
UK).
2.10. Imaging
An IVIS ultrasensitive camera (Xenogen) was used to Image
3x-B-luc mice essentially as previously outlined [29]. Mice were
anesthetized with isoﬂurane and hair removed from the abdomi-
nal region by shaving. d-Luciferin (120mg/kg) dissolved in 200l
PBS, pH 7.8, was injected i.p. and mice were placed in the IVIS
imaging chamber and a luminescence reading collected (for 2min)
10min later. Mice were then killed by cervical dislocation, blood
was collected for serum analysis and organs removed for imaging
(performed35min after injection of luciferin). All imageswere pro-
cessed with the software Image-Pro Plus 4.0 (Media Cybernetics,
Silver Spring, MD) integrated with the HPD-LIS module developed
by Hamamatsu.
3. Results
3.1. PXR activation inhibits inﬂammation in an animal model of
PTI
The SJL/J mouse strain is resistant to the induction of immune
tolerance [30,31], is susceptible to cell sarcomas [32] and has been
used as a model for several autoimmune diseases [33–36]. PTI
and cholangitis is also observed in this strain of mice [37,38]. To
determine whether PXR activation affects PTI, female PXR+/+ and
PXR−/− mice were generated on an SJL/J background (SJL/J-PXR+/+
and SJL/J-PXR−/−) and treated between 8 and 16 weeks of age with
the rodent-speciﬁc PXR activator PCN (Fig. 1A). Fig. 1B conﬁrms
that there was an induction of the PXR-inducible cyp3a11 mRNA
[1,23], indicating that mice were exposed to sufﬁcient levels of
PCN to activate the PXR and bring about a change in hepatic PXR-
dependent gene expression in mice with a functional PXR. The lack
of induction of cyp3a11 in SJL/J-PXR−/− conﬁrms functional knock-
out of the PXR gene in these mice [23]. Fig. 1B also shows that
PCN treatment signiﬁcantly inhibited the expression of TNF and
Il-1 mRNA expression in SJL/J-PXR+/+ mice, but not SJL/J-PXR−/−
mice, demonstrating that PCN reduced expression of these pro-
inﬂammatory cytokines via the PXR. A statistically non-signiﬁcant
reduction in hepatic TNF mRNA was observed in PCN-treated
SJL/J-PXR−/− mice, which may have become signiﬁcantly lower
(though less so than in PCN-treated SJL/J-PXR+/+ mice) if the num-
bers of animals in each group were larger. This may be associated
with a PXR-independent effect of PCN as previously observed in
ﬁbrosis models caused by CCl4 [5]. The target for PCN mediating
this PXR-independent effect remains unidentiﬁed.Other cytokines—Il-1, Il-6 and Il-10 were not signiﬁcantly
affected by PCN treatment (data not shown). Fig. 1C and D demon-
strates that PXR activation in these animals also had a functional
effect on hepatic inﬂammation since PTI was signiﬁcantly reduced
in SJL/J-PXR+/+ – but not SJL/J-PXR−/− – mice, by PCN treatment.
140 K. Wallace et al. / Journal of Steroid Biochemistry & Molecular Biology 120 (2010) 137–148
Fig. 1. PCN inhibits PTI in SJL/Jmice via thePXR. (A) Schematic diagramof the experimental approachemployed to examine the effects of PXRactivationonPTI. (B)Quantitative
RT-PCR analysis for the mRNA transcript indicated. Data expressed relative to its equivalent genotype control. *Signiﬁcantly different (P>95%) transcript level versus control
group using Student’s t-test (two tailed). (C) Typical views of H&E stained liver sections from treatment groups as indicated. (D) Quantitation of the number of inﬂammatory
cells present in portal tracts. At least 10 portal tracts from each animal were randomly selected by an examiner blinded to the treatment and the number of inﬂammatory
cells determined. A separate blinded examiner determined the total area of bile duct in each ﬁeld of view. The mean PTI for each animal was calculated and data are expressed
as the mean and standard deviation PTI for 4 animals per treatment group. Total area and number of bile ducts between groups (data not included) did not signiﬁcantly differ
between treatment groups, suggesting that quantitation is not biased to size of portal regions of the liver. *Signiﬁcantly different (P>95%) number cells versus control group
using Student’s t-test (two tailed).
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hese data therefore indicate that the PXR mediates an anti-
nﬂammatory effect of PCN in vivo.
.2. The activated PXR inhibits NF-B and TNF˛ expression in
onocytic cells
TNF is a potent pro-inﬂammatory cytokine expressed by
onocytic cells. Induction of TNF expression is regulated by the
ranscription factor NF-B [15]. To determine whether PXR acti-
ation inhibits NF-B, the human monocytic U937-3XB-LUC cell
inewas treatedwith the toll-like receptor 4 (TLR4) ligand bacterial
PS to activate NF-B (these cells only responded to LPS and TNF
mongst a range of other activators examined—see Supplementary
ig. 1). Fig. 2A demonstrates that the U937-3XB-LUC cell line
xpressed the PXR mRNA (quantitatively, both Hep-G2 and U937-
XB-LUC cells express lower but signiﬁcant (∼50%) levels of PXR
RNA when compared to human liver—Supplementary Fig. 2).
Fig. 2B shows that co-treating cellswith LPS and IKK inhibitors –
ulfasalazine (SULF) and IKK2-In – or the 20S proteasomal inhibitor
liotoxin (GT) inhibited luciferase expression induced by LPS (and
NF—Supplementary Fig. 2) as expected since these compounds
re known to inhibit the activation of NF-B [39,40]. However,
ig. 2B indicates that humanPXRactivators RIF, HYP andMET [9,41]
lso inhibited luciferase expression whereas the rodent-speciﬁc
XR activator PCN had no effect.
Fig. 2C demonstrates that none of the compounds – at the
oncentrations chosen to investigate effects on NF-B activity –
howed overt signs of causing toxicity with or without LPS treat-
ent, as judged by trypan blue exclusion after 5h of incubation. In
ontrast chlorpromazine, which has been shown to cause necrosis
n a range of cell types [42], killed all cells by 5h. Higher concen-
rations of IKK2-In and GT did show signs of toxicity, whereas none
f the PXR activators caused toxicity at 10-fold the concentration
mployed to examine effects on NF-B activity. These data were
ssentially conﬁrmed by MTS dye reduction (Supplementary Fig.
) and indicate that the inhibition of NF-B by PXR activators is not
ssociated with any effects on cell viability.
PXR activators did not inhibit TNF-induced luciferase expres-
ion (Supplementary Fig. 2) although it should be noted
hat TNF treatment stimulated U937-3XB-LUC cell apoptosis
Supplementary Fig. 4) which may have abrogated any PXR-
ependent inhibition of NF-B.
To determine whether PXR activation is able to inhibit tran-
cription of TNF expression, the human monocytic THP-1 cell
ine (which was more amenable to transfection than U937-
XB-LUC cells) was transfected with a luciferase reporter gene
onstruct under control of the TNF gene promoter gene sequence.
ig. 3A shows that the THP-1 cell readily trans-activated reporter
ene expression in comparison to liver myoﬁbroblasts (LX-2)
r hepatocye-like (Hep-G2) cells although trans-activation was
esponsive to TNF treatment in all cell types, only THP-1 cells
esponded to LPS, likely associated with its expression of the
LR4–see Fig. 3B. Fig. 3C demonstrates that constitutive reporter
ene expression was inhibited by the human PXR activators RIF,
YP and METYR (but not the rodent-speciﬁc PXR activator PCN)
nd the IKK inhibitors SULF and IKK2-In in THP-1 cells (which also
xpressed the PXR, see Fig. 3D). This inhibitory responsewas essen-
ially alsoobserved inTHP-1 cells treatedwithTNFor LPS (Fig. 3C).
XR and IKK inhibitors also inhibited TNF-induced reporter gene
xpression in LX-2 cells (Fig. 3C).
To test the relevance of these observations to inﬂammation and
iver disease, Kupffer cells were isolated from human liver resected
rom 5 individuals. These cells were conﬁrmed positive for the
xpression of the monocyte/macrophage marker ED1 (CD68) [43];
he uptake of latex beads [44] and expression of TNF in response
o LPS (Supplementary Fig. 5). Fig. 3D and E shows that the Kupffer& Molecular Biology 120 (2010) 137–148 141
cells expressedPXRmRNAand that humanPXRactivators inhibited
LPS-inducedsecretionofTNF. Fig. 3F indicates that this response is
likely to be mediated via the PXR since LPS-dependent TNF secre-
tion from Kupffer cells isolated from PXR−/− mice was not affected
by PCNwhereas PCN inhibited secretion fromKupffer cells isolated
from PXR+/+ mice.
3.3. PXR activation inhibits NF-B activation in vivo
CCl4 is a pro-toxin that is metabolised primarily by cytochrome
P450 2e1 to a radical species which forms a reactive peroxy-radical
that initiates lipid peroxidation and cell damage in the liver [8].
We have previously shown that PCN did not interfere with the
metabolism or toxicity of CCl4 in both rats and mice and that
the anti-ﬁbrogenic effects of PCN were independent of a modu-
lation of toxicity [5]. CCl4 was therefore administered to 3x-B-luc
C57BL/6J×CBA/J mice for 4 weeks to generate a chronic injury and
inﬂammation. At the ﬁnal injury, PCN or vehicle was administered
(Fig. 4A) and the level of NF-B activation (via luciferase trans-
gene expression) determined in the liver in vivo 24h later. Fig. 4B
demonstrates that CCl4 treatment induced NF-B activity and that
light emission in whole body imaging was primarily associated
with emission from the liver since nearby organs (kidney, spleen
and stomach) showed markedly lower light emission than the liver
after dissection (Fig. 4C). PCN treatment signiﬁcantly reduced NF-
B activity in CCl4-treated mice (Fig. 4D) without affecting liver
damage as judged by serumALT levels (Fig. 4E) or throughhistolog-
ical examination of ﬁxed liver sections after H&E staining (data not
shown). The lackof effect of PCNonhepaticnecrosis in these studies
is consistent with previous investigations and therefore suggests
that PCN inhibits NF-B by some other mechanism(s)
3.4. CsA is a PXR activator
PBC is a chronic cholestatic inﬂammatory liver disease of
unknown cause. Chronic PTI and ﬁbrosis is untreatable and leads
to cirrhosis and the need for liver transplantation. A recent report
has determined that PBC disease re-emerges in PBC patients faster
post-transplant when they were maintained on the anti-rejection
drug FK506 compared to patients on CsA [21]. Fig. 5A demonstrates
that CsA – but not FK506 – was a PXR activator in a human PXR
trans-activation reporter gene assay. This was conﬁrmed in human
hepatocytes which classically respond to the potent PXR ligand RIF
withhigh levelsofCYP3A4 inductionvia its activationof thePXR [9].
Fig. 5B shows that CsA – but not FK506 – induced CYP3A4 protein
in human hepatocytes. Since CYP3A4 is also regulated by FXR [45],
a colon cell line (LS180) was tested since these cells did not express
the FXR but retained PXR expression (Fig. 5C). CsA induced CYP3A4
mRNA (Fig. 5D) suggesting that CsA activates, either directly or
by some intermediary mechanism, at least the PXR to mediate its
effects on CYP3A4 mRNA.
4. Discussion
Liver damage is primarily associated with hepatocyte necrosis
and an inﬂammatory response that is a component of the stimulus
for regeneration and repair. With chronic damage, ﬁbrosis occurs
which, although considered an essential response to repair, may
have a pro-inﬂammatory effect that in some individuals, leads to
an exacerbation of disease. There is good evidence to suggest that a
reduction in ﬁbrosis may improve the liver’s response to on-going
insult [40,46]. Inﬂammation is a component of ﬁbrosis and there-
fore an inhibition of inﬂammation may also have a similar effect.
Currently there is no treatment available for chronic liver disease
and liver ﬁbrosis [8].
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Fig. 2. Effect of PXR activators on NF-B-dependent gene expression in U397-3XB-LUC cells. (A) Left panel, RT-PCR for PXR and GAPDH in U937-3XB-LUC cells, Hep-G2
cells and human skin ﬁbroblasts (Skin FB). Each lane is ampliﬁed product from the equivalent 50ng template total RNA per well, 35 PCR cycles). (B) Luciferase activity after
5h treatment with the indicated compounds (DMSO, 0.5% (v/v); RIF, 20M; HYP, 1M; METYR, 250M; PCN 20M; SULF 1mM; IKK2-In 10M; GT, 3M) normalised to
LPS+DMSO vehicle activity. Data are themean and standard deviation of 3 determinations from the same experiment, typical of at least 4 separate experiments. *Signiﬁcantly
different (P>95%) reporter gene expression versus LPS-induced DMSO control using Student’s t-test (two tailed). (C) Trypan blue exclusion. Upper panels, light micrographs
of typical views 5h after treatment with 300ng/ml LPS and the indicated compound. Lower panel, percentage trypan blue exclusion in U937-3XB-LUC cells treated with
300ng/ml LPS and the indicated concentration of compound for 5h (note, grey bars are the concentrations employed to examine effects on NF-B activity in B). Data
are the mean of 3 separate incubations from the same experiment, typical of 3 separate experiments. Insol, compound became insoluble when added to culture medium.
*Signiﬁcantly different (P>95%) trypan blue exclusion versus LPS-induced vehicle control (DMSO) using Student’s t-test (two tailed). Similar results were obtained with
compounds without the addition of LPS (data not shown).
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The PXR is a nuclear receptor that regulates the expression of
he major drug metabolising enzymes in human liver, collectively
eferred to as the cytochrome P450 3A sub-family. These enzymes
re expressed at high levels in hepatocytes. Like many cytochrome
450s, they have endogenous functions, which for CYP3A4 in the
iver, is to metabolise bile acids to more water soluble/excretable
roducts [23,47]. This canonical functionof thePXR is likely tobe an
ig. 3. Effect of PXR activators or NF-B inhibitors on TNF-promoter reporter gene exp
oth with renilla plasmid RL-TK (10:1 ratio). After 24h, cells were treated as indicated (D
KK2-In 10M; GT, 3M) and after a further 24h, cells were harvested and reporter gen
xperiments, signiﬁcantly different (P>95%) reporter gene expression versus *untreated
MSO control using Student’s t-test (two tailed). (B) RT-PCR for TLR4 and TNFR1 in the v
er well, 35 PCR cycles). (D) RT-PCR for human PXR and glyceraldehyde phosphate dehy
he equivalent 50ng template total RNA per well, 35 PCR cycles). (E) percentage secretion
ells were incubated with the indicated PXR activator (RIF or HYP) added from a 1000-
ontrol. Data are the mean and standard deviation of results from 3 separate patient cel
tudent’s t-test (two tailed). (F) TNF secretion by Kupffer cells isolated from PXR+/+ or P
ncubations from a single pool of cells versus DMSO treated cells. DMSO, 0.5% (v/v); PCN, 2
xperiments. Signiﬁcantly different (P>95%) compared to *DMSO or ¶LPS-treated cells us& Molecular Biology 120 (2010) 137–148 143
advantage in cholestatic liver disease since it would promote the
urinary excretion of toxic bile acids [23]. Previous work suggests
that there is a non-canonical anti-ﬁbrotic role for the PXR since
activators inhibited ﬁbrosis in animal models of chronic liver dis-
ease. The myoﬁbroblast – the major contributor to ﬁbrosis – was
shown to be particularly responsive to PXR activators in human
cells in vitro [6]. Human myoﬁbroblasts were shown to express
ression. (A and C) Cells were transfected with either pXP1 (EMPTY) or TNF-Prom,
MSO, 0.5% (v/v); RIF, 20M; HYP, 1M; METYR, 250M; PCN 20M; SULF 1mM;
e expression determined. Data are the mean and standard deviation of 3 separate
or DMSO vehicle control; $versus TNF-induced DMSO control or ¶LPS-induced
arious cell types (ampliﬁed product from the equivalent 50ng template total RNA
drogenase (GAPDH) transcripts in the indicated cell types (ampliﬁed product from
of TNF over 24h by human Kupffer cells versus LPS treatment alone (100% arb).
fold molar concentrated stock in dimethyl sulfoxide (DMSO). DMSO, 0.1% (v/v) as
l preparations. *Signiﬁcantly different secretion (P>95%) versus LPS+DMSO using
XR−/− mice expressed as the mean and standard deviation levels from 3 separate
0M from a 4mM stock in DMSO, LPS, 100ng/ml. Results are typical of 3 separate
ing Student’s t-test (two tailed).
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igh levels of PXR yet these cells did not express the genes reg-
lated by the PXR in hepatocytes [6]. The function of the PXR in
hese cells is unclear, however the effects of PXR activation were
triking, with RIF maintaining cells in a quiescent non-ﬁbrogenic
henotype in vitro for several weeks [6]. Since these discoveries,
he PXR has been shown to be anti-inﬂammatory in the gut [19,20]
nd therefore we investigated a potential anti-inﬂammatory role
n the liver.
The data in this paper indicate that PXR activation inhibited PTI
n the SJL/J mice and reduced the levels of inﬂammatory cytokines
uchasTNF in the liver. TNF is expressedprimarilybymonocytes
nd macrophages, suggesting that the effects observed in these
xperiments are likely associated with a direct effect of PXR activa-
ion in these cell types. This potential was conﬁrmed in vitro using
onocyte and macrophage cells. These cell types expressed the
XR, and NF-B – the major transcriptional regulator of inﬂamma-
ory gene expression–was shown tobe inhibitedbyPXRactivators.inued ).
Imaging experiments conﬁrmed PXR activation inhibited liver NF-
B activity in vivo.
Activation of the PXR in a chronically damaged liver may there-
fore have at least 4 potential beneﬁts with regard to ameliorating
the effects of chronic cholestatic liver disease. The ﬁrst is the well
established promotion of hepatocyte growth [48,49], an essential
requirement in a liver that is losing functional capacity. The sec-
ond is an increase in cytochrome P450 3A expression, which will
enhance the ability of the liver to reduce toxic bile acid levels [23].
The third is an inhibition in ﬁbrosis [5,6]. The ﬁnal beneﬁt – indi-
cated by these experiments – is an inhibition of inﬂammation. All
these factors impact upon each other and it is likely that the inhi-
bition of ﬁbrosis previously observed was dependent in part, on an
effect on inﬂammation.
Increasing attention is being paid to the cross-talk that occurs
between nuclear receptors and signalling pathways regulating
inﬂammation. In this respect, cross-talk between the peroxiome
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Fig. 4. PCN inhibits hepatic NF-B transcriptional activity induced by CCl4 treatment in vivo. (A) Schematic diagram of the experimental approach employed to examine the
effects of PXR activation on NF-kB. (B) Light production from a corn oil control and CCl4-treated mouse 24h after treatment, 10min after injection of d-luciferin. (C) Light
production from the indicated organs removed from a corn oil or CCl4-treated mouse, 35min after injection of d-luciferin. Data are typical of at least 3 animals/treatment
group. (D) Total light production from the abdominal region of mice 24h after treatment as indicated. (E) Serum ALT activity from imaged mice 24h after treatment as
indicated. Data are the mean and standard deviation of at least 3 animals per treatment group. *Signiﬁcantly different from corn oil and PCN, $signiﬁcantly different from
CCl4 using ANOVA statistical test.
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Fig. 5. CsA is an activator of the human PXR. (A) Hep-G2 cells cultured in 24-well plates were transfected with 0.5g (ER6)3-pGL3promoter and 0.05g RL-TK/well and PXR
activation determined [6]. Data are the mean and standard deviation of at least 3 separate transfections from the same experiment expressed as fold normalised luciferase
expression versus DMSO vehicle control, typical of at least 3 separate experiments. *Signiﬁcantly different (P>95%) luciferase activity versus DMSO using Student’s t-test
(two tailed). (B) Human hepatocytes were isolated and cultured as outlined in Methods section and treated with the indicated compounds after the ﬁrst 24h of culture
(T0) for a further 48h prior to isolation and analysis of CYP3A4 and -actin levels by Western blotting. Medium and treatments were replenished every 24h. (C) RT-PCR for
the indicated transcripts in human liver, two separate human hepatocyte preparations (freshly isolated cells) and two separate LS180 cultures (ampliﬁed product from the
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.1% (v/v); RIF, 20M RIF (for 48h) and CsA and FK506 at the indicated concentra
ranscript CYP3A4 and 18S rRNA levels determined by quantitative RT-PCR. *Signiﬁ
ailed).
roliferator activated receptor  (PPAR) and NF-B activity has
een most intensely studied. Expression of PPAR is regulated
y LPS [50] and activation of PPAR is also anti-inﬂammatory
51–54] via direct protein-protein interaction with NF-B in a
NA binding-independent mechanism [55,56]. PPARmay also be
UMOylated, which can function to inhibit the loss of transcrip-
ional co-repressors from NF-B target genes [57]. Some of these
echanismsmay also be involved in the PXR-dependent inhibition
f inﬂammation.
The clinical evidence for a potential effect of PXR activators
n chronic liver disease is scarce but indicative of beneﬁt. Tri-
ls with RIF have shown that this compound reduced serum
evels of alkaline phosphatase, a marker of cholestatic liver dis-
ase [58,12]. Effects on inﬂammation and ﬁbrosis have not to
ur knowledge, been examined. RIF – although a potent activa-
or of the human PXR – is associated with adverse hepatotoxic
ffects [59]. However, this is not associated with its interaction
ith the PXR but likely due to effects on mitochondria. Thus,
ther PXR activators – which do not have these latter effects –
ould be more effective. However, the current safe use of RIF in
group of chronic liver disease patients could be extended to use
n other groups relatively rapidly and without signiﬁcant ﬁnancial
urden.RNA in LS180 cells. LS180 cells were treated with the indicated compound DMSO,
for 72h. Culture media and treatments were changed daily. RNA was isolated and
different (P>95%) transcript level activity versus DMSO using Student’s t-test (two
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